Sanguinate by Prolong Pharmaceuticals for Sickle Cell Disease With Vaso-Occlusive Crisis: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sanguinate overview

Sanguinate is under development for the treatment sickle cell diseases (SCD) associated vaso-occlusive crisis, beta-thalassemia and cystic fibrosis. The drug candidate is administered through intravenous route. The therapeutic candidate is a PEGylated hemoglobin. It is a Hemoglobin-based oxygen carrier (HBOC). It was under development for the treatment of ischemia-reperfusion injury in myocardial infarction, delayed graft function in recipients of kidney transplantation after donation, delayed cerebral ischemia after acute aneurysmal subarachnoid hemorrhage, end-stage renal disease and other sickle cell diseases (SCD) associated leg ulcers.

Prolong Pharmaceuticals overview

Prolong Pharmaceuticals is a clinical stage biopharmaceutical company that offers anemia care drugs. It develops products to treat several diseases and their debilitating comorbidities associated with reduced quality of life. Its Sanguinate product is in clinical development for treating sickle cell disease and other disorders caused by anemia or hypoxia and ischemia. Prolong Pharmaceuticals also has four products in development for hematology and oncology indications. The company has been associated with a number of successful pharmaceutical and biotechnology companies. Pharmaceuticals is headquartered in South Plainfield, New Jersey, the US.

For a complete picture of Sanguinate’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.